BridgeBio Pharma
BBIO
263 hedge funds and large institutions have $4.85B invested in BridgeBio Pharma in 2024 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 104 increasing their positions, 80 reducing their positions, and 36 closing their positions.
404% more call options, than puts
Call options by funds: $389M | Put options by funds: $77.2M
36% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 36
30% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 80
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
10% more capital invested
Capital invested by funds: $4.39B → $4.85B (+$454M)
4% more funds holding
Funds holding: 253 → 263 (+10)
1.7% more ownership
Funds ownership: 91.78% → 93.48% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$63.3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$32.6M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$24.3M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$23.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$43.6M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$25.7M |
| 3 |
JP Morgan Chase
New York
|
-$23.7M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$19.9M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$18.8M |
BBIO Hedge Fund Activity: Q4 2024 in Review
263 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2024, worth a combined $4.85B — up 10% from $4.39B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new BBIO positions and 36 closed out — a net gain of 13 holders — while 104 added to existing stakes and 80 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $63.3M. The largest seller was Citadel Advisors, cutting an estimated $43.6M.
- 263 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2024, up from 253 in Q3 2024.
- Funds reported $4.85B of BridgeBio Pharma stock for Q4 2024, up 10% quarter-over-quarter.
- 49 funds opened new BridgeBio Pharma positions in Q4 2024 and 36 closed out, a net change of +13 holders.
- The largest BridgeBio Pharma buyer in Q4 2024 was Farallon Capital Management, an estimated $63.3M added.
- The largest BridgeBio Pharma seller in Q4 2024 was Citadel Advisors, an estimated $43.6M sold.
Based on aggregated 13F filings for Q4 2024.